Plerixafor (CXCR4 antagonist) and natalizumab (anti-VLA-4 antibody) are the agents that could inhibit the interaction of MCL to stromal cells keeping these MCL cells in a mobilized state; these mobilized MCL cells are more susceptible to standard therapies [149]. This evidence concerns the gene CXCR4 and mantle cell lymphoma.